Hereditary deafness is transferred from parents to the child or it can be developed gradually during childhood or adulthood. It can be autosomal dominant or recessive, X-linked, or mitochondrial-related. Hearing loss that is present at birth is known as congenital hearing loss.
Hereditary factors responsible for hearing loss include Pendred syndrome, Usher syndrome, and otosclerosis.
A hereditary hearing loss can be both conductive hearing loss and sensorineural hearing loss. Inner ear sensory hair cells play a crucial role in hearing, as they transmit sound from the inner ear through the cochlear nerve to the brain, and any damage to these tiny hair cells results in a sensorineural hearing loss.
A sensorineural hearing loss can occur in both ears (bilateral hearing loss) or in one ear (unilateral hearing loss). Conductive hearing loss occurs when the sound cannot get through the middle and outer ear.
Global Hereditary Deafness Market– Dynamics
The rising prevalence of hearing loss across the globe is expected to propel the global hereditary deafness market growth. For instance, on April 01, 2021, according to the data published by the World Health Organization (WHO), it is expected that by 2050, around 2.5 billion people of global population will have some extent of hearing loss and at least 700 million will need hearing rehabilitation.
Recent product launches and approvals is expected to boost the global hereditary deafness market growth. For instance, on March 18, 2020, Cochlear Medical Device Company India Pvt Ltd, received the U.S. Food and Drug Administration approval for Cochlear nucleus implantsto lower the age criteria for cochlear implantation from 12 months to 9 months for children having congenital deafness.
Moreover, on June 17, 2019, Cochlear Medical Device Company India Pvt Ltd, received the U.S.FDA clearance for the Cochlear Osia 2 System, which is a new category of bone conduction hearing solutions.
Similarly, on June 29, 2020, the U.S. Food and Drug Administration acknowledged the Breakthrough Device Designation to Envoy Medical Corporation’s, Acclaim cochlear implant.
Furthermore, on August 26, 2020, MED-EL’s new lightweight and slim RONDO 3 audio processor received U.S. FDA approval for the SYNCHRONY Cochlear Implant System.
In addition, rising ongoing clinical trials of drugs is expected to augment the hereditary deafness market growth. For instance, on July 23, 2020, Pipeline Therapeutics, a biopharmaceutical company announced the initiation of Phase 1/2a trial of a gamma secretase inhibitor, PIPE-505, in sensorineural hearing loss. These factors are expected to drive the global hereditary deafness market growth over the forecast period.
Global Hereditary Deafness Market– Regional Insights
North America is expected to dominate the global hereditary deafness market, owing to the rising prevalence of hearing loss among infants in the U.S. For instance, in 2019, as stated in the data of the Centers for Disease Control and Prevention (CDC), in the U.S. among the 98% newborns, around 6,000 infants born in 2019 were detected with a permanent hearing loss. The prevalence of congenital hearing loss was 1.7 per 1,000 babies screened for hearing loss in 2019.
Moreover, Europe is estimated to witness lucrative growth over the forecast period, owing to rising research and development activities to develop advanced hearing aids. For instance, on August 18, 2020, GN Hearingone of the hearing aid innovator launched ReSound ONE, a novel hearing aid. This new class of solution let people rely on hearing device, while procuring the comfort of the aid. These factors are expected to fuel global hereditary deafness market growth over the forecast period.
Global Hereditary Deafness Market – Taxonomy
By Product Type:
By End User:
Global Hereditary Deafness Market– Competitive Landscape
Key players operating in the global hereditary deafness market include Cochlear Medical Device Company India Pvt Ltd, Envoy Medical Corporation, MED-EL GmbH, Advanced Bionics, Nurotron Biotechnology Inc., Oticon Medical, Medtronic, Sonova Hearing India Pvt., Audina Hearing Instruments Inc., RION Co., Ltd., GN Hearing, Decibel Therapeutics Inc., and Frequency Therapeutics, and Pipeline Therapeutics, Inc.